Change on the horizon…hopefully good

I saw my psych doctor today to talk about my depression and anxiety.  My antidepressants aren’t helping anymore.  I’m on Effexor and have been for many years and it’s not working for me anymore.  We are going to wean me off the Effexor and starting Trintellix (a newer med).  It’s not going to be an easy time weaning off the Effexor because I have been on it so long.  I pray that it is an easy transition onto the new med.  I need a break through.  I deserve a win in this one. Continue reading

Depression on a rainy day

Depression on a rainy day is no fun.  Depression itself is no fun to live with.  Depression on a holiday where we honor the men and women who paid the ultimate sacrifice for our country is not easy either.  Reading/hearing all the stories of the fallen heroes is hard when you are not having a good mental day.  I got teary eyed (as usual) as the XM radio’s “The Highway” played “Taps” to honor those killed in action.  This weekend has been hard one for me and I don’t really know why.   Continue reading

Clinic Update

It was a good clinic visit today.  It’s always good when they say that you look the best they have seen you look in awhile.  I don’t know if I can attribute that to the Symdeko or just feeling decent.  I’m not trying to sound like a doubting Debbie but I just haven’t had any major “ah ha moments” to convince me it is symdeko but I should stop that way of thinking.  It is obviously working for the better, especially since I haven’t had any of the side effects. Continue reading

On a new journey…

A few months ago I shared about the new CF drug Symdeko (Symdeko post).  After much tossing around of the idea of taking the new drug I finally decided to give it a try.  I started the drug 3 days ago.  It is twice a day and I have to take it with a meal/snack containing a good amount of fat to help it absorb.   Continue reading

New CF drug!

New CF Combo Therapy, Symdeko by Vertex, Approved by FDA for Certain Patients

Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Symdeko (tezacaftor/ivacaftor and ivacaftor) as a therapy for cystic fibrosis (CF) patients carrying two copies of the F508del mutation in the CFTR gene (the gene defective in CF) or with one mutation that responds to tezacaftor/ivacaftor. Continue reading